Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 14/20 | 0.52 |
| ▸ | CDK2 | P24941 | 14/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 13/20 | 0.52 |
| ▸ | CDK4 | P11802 | 8/20 | 0.51 |
| ▸ | CCND1 | P24385 | 8/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.51 |
| ▸ | CDK1 | P06493 | 6/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.51 |
| ▸ | PRKCH | P24723 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | ITK | Q08881 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196179 | 0.91 | CDK2 (0.52) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL6198203 | 0.91 | CCNE1 (0.51) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL6197756 | 0.86 | CCNE1 (0.52) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL6196476 | 0.83 | CDK2 (0.43) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL6222327 | 0.78 | CCNE2 (0.82) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL7692356 | 0.77 | CCNE1 (0.58) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL6196475 | 0.77 | LMNA (0.42) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL3467838 | 0.73 | HDAC3 (0.63) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL4213621 | 0.73 | HDAC3 (0.72) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL3478233 | 0.73 | HDAC3 (0.62) | CCNE1CDK2CCNE2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303512-B1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | BRISTOL MYERS SQUIBB CO (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20030216440-A1 | Process for preparing arylacetylaminothiazoles | CHEN BANG-CHI (US) | 2003-11-20 | — | — | US | disclosed |
| US-6613911-B2 | Reaction of haloarylacetic acids or esters with olefins to give vinylarylacetic acids or esters, oxidation with an oxidizing reagent gives formylarylacetic acids or esters | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-02 | — | — | US | disclosed |
| EP-1303512-A1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | Bristol-Myers Squibb Company (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20020072609-A1 | Process for preparing arylacetylaminothiazoles | CHEN BANG-CHI (US) | 2002-06-13 | — | — | US | disclosed |
| US-6392053-B2 | INCLUDES REACTING HALOARYLACETIC ACIDS OR ESTERS WITH OLEFINS TO GIVEN VINYLACRYLACETIC ACIDS OR ESTERS, FOLLOWED BY OXIDATION TO FORM THE FORMYLARYLACETIC ACID INTERMEDIATE; CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-21 | — | — | US | disclosed |
| WO-2002010161-A1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-07 | — | — | WO | disclosed |
| US-20010004639-A1 | Process for preparing arylacetylaminothiazoles | BRISTOL-MYERS SQUIBB COMPANY | 2001-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216440-A1 | Process for preparing arylacetylaminothiazoles | CCNI, CCNT1, CCNA1 | CCNE1 6/4885CDK2 5/4885CCNE2 23/4885 |
| US-20020072609-A1 | Process for preparing arylacetylaminothiazoles | CCNT1, CCNI, CCNA1 | CCNE1 7/4885CDK2 6/4885CCNE2 26/4885 |
| US-20010004639-A1 | Process for preparing arylacetylaminothiazoles | CCNI, CCNA1, CCNT1 | CCNE1 6/4885CDK2 5/4885CCNE2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.